大湾生物

Fc platform is to combine IgG’s Fc fragment with unstable/short half-life peptide, cytokine, hormone or enzyme to form fusion protein, so to extend the half-life in vivo and lower frequency of administration.

We choose Fc fragment of IgG2 sub-type (wild type) or IgG4 sub-type (S228P mutation) to combine with different peptide for expression, and now we have 1 projects in progress, which one is rhEPO-Fc in clinical phase 1.

The greatest characteristics of platform is to utilize CMC platform to quickly process pre-clinical works, including molecule structure stability research, in vitro bioactivity research, sample preparation for animal pharmacodynamics study, etc. to have quick judgement on feasibility of drug development project.